{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:11:51Z","timestamp":1793121111706,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijbiomac.2026.153509","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:53:08Z","timestamp":1783781588000},"page":"153509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Recombinant Sgp130 attenuates alkali-burn cornea through inhibition of IL-6 trans-signaling: From production to therapeutic application"],"prefix":"10.1016","volume":"377","author":[{"given":"Long-Bin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Hao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-li","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0005","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.bbamcr.2011.01.034","article-title":"The pro- and anti-inflammatory properties of the cytokine interleukin-6","volume":"1813","author":"Scheller","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153509_bb0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0015","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cytogfr.2023.12.007","article-title":"Navigating IL-6: from molecular mechanisms to therapeutic breakthroughs","volume":"76","author":"Swaroop","year":"2024","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0020","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2147\/ITT.S485684","article-title":"IL-6 signaling in immunopathology: from basic biology to selective therapeutic intervention","volume":"14","author":"Schumertl","year":"2025","journal-title":"Immunotargets Ther."},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.153509_bb0025","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6.Soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0030","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153509_bb0035","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1043-4666(05)80007-9","article-title":"Overall interleukin-6 production exceeds 7 mg\/day in multiple myeloma complicated by sepsis","volume":"5","author":"Lu","year":"1993","journal-title":"Cytokine"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155690","article-title":"Blocking only the bad side of IL-6 in inflammation and cancer","volume":"148","author":"Rose-John","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155577","article-title":"Therapeutic targeting of IL-6 trans-signaling","volume":"144","author":"Rose-John","year":"2021","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153509_bb0050","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.cytogfr.2020.04.003","article-title":"Biological functions and therapeutic opportunities of soluble cytokine receptors","volume":"55","author":"Lokau","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153509_bb0060","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0065","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jacbts.2021.01.013","article-title":"Selective Interleukin-6 trans-signaling blockade is more effective than panantagonism in reperfused myocardial infarction","volume":"6","author":"George","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153509_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ajpath.2017.10.011","article-title":"Distinct effects of IL-6 classic and trans-signaling in bone fracture healing","volume":"188","author":"Prystaz","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0075","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00210-018-1483-7","article-title":"Pharmacological inhibition of IL-6 trans-signaling improves compromised fracture healing after severe trauma","volume":"391","author":"Kaiser","year":"2018","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153509_bb0080","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1172\/JCI64931","article-title":"IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality","volume":"123","author":"Zhang","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.758233","article-title":"Case report: arterial wall inflammation in atherosclerotic cardiovascular disease is reduced by Olamkicept (sgp130Fc)","volume":"13","author":"Schulte","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0090","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13832","article-title":"Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: results from randomized, placebo-controlled, first-in-human phase I trials","volume":"17","author":"Wagner","year":"2024","journal-title":"Clin. Transl. Sci."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153509_bb0095","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1001\/jama.2023.1084","article-title":"Effect of induction therapy with Olamkicept vs placebo on clinical response in patients with active ulcerative colitis: a randomized clinical trial","volume":"329","author":"Zhang","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153509_bb0100","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2021.02.062","article-title":"Therapeutic interleukin-6 trans-signaling inhibition by olamkicept (sgp130Fc) in patients with active inflammatory bowel disease","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109748","article-title":"The role of the JAK\/STAT3 signaling pathway in acquired corneal diseases","volume":"238","author":"Song","year":"2024","journal-title":"Exp. Eye Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.153509_bb0110","article-title":"Emerging strategies in treating corneal alkali burns: a narrative review","volume":"15","author":"Mittal","year":"2023","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153509_bb0115","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jtos.2016.09.002","article-title":"Current and upcoming therapies for ocular surface chemical injuries","volume":"15","author":"Baradaran-Rafii","year":"2017","journal-title":"Ocul. Surf."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153509_bb0120","doi-asserted-by":"crossref","first-page":"e746","DOI":"10.1111\/aos.13096","article-title":"Inhibition of HIF-1alpha decreases expression of pro-inflammatory IL-6 and TNF-alpha in diabetic retinopathy","volume":"95","author":"Gao","year":"2017","journal-title":"Acta Ophthalmol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153509_bb0125","doi-asserted-by":"crossref","first-page":"136","DOI":"10.5935\/0004-2749.20190021","article-title":"Correlation of the aqueous humor total antioxidant capacity, total oxidant status, and levels of IL-6 and VEGF with diabetic retinopathy status","volume":"82","author":"Bozkurt","year":"2019","journal-title":"Arq. Bras. Oftalmol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.153509_bb0130","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/jcph.1406","article-title":"Monoclonal antibodies and fc-fusion proteins for pediatric use: dosing, immunogenicity, and modeling and simulation in data submitted to the US Food and Drug Administration","volume":"59","author":"Liu","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108434","article-title":"Daphnetin inhibits corneal inflammation and neovascularization on a mouse model of corneal alkali burn","volume":"103","author":"Yang","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.107982","article-title":"Keratocytes promote corneal neovascularization through VEGFr3 induced by PPARalpha-inhibition","volume":"193","author":"Wang","year":"2020","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ajo.2018.09.017","article-title":"Fluorometholone 0.1% as ancillary therapy for trachomatous trichiasis surgery: randomized clinical trial","volume":"197","author":"Kempen","year":"2019","journal-title":"Am. J. Ophthalmol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153509_bb0150","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/09273948.2016.1277247","article-title":"Roles of IL-6 in ocular inflammation: a review","volume":"26","author":"Ghasemi","year":"2018","journal-title":"Ocul. Immunol. Inflamm."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2026.1805665","article-title":"The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting","volume":"17","author":"Harlow","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2025.1546105","article-title":"mAb production kinetics in CHO batch culture: exploring extracellular and intracellular dynamics","volume":"13","author":"Avilan Garzon","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0165","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/19420862.2015.1019788","article-title":"Fusion protein technologies for biopharmaceuticals: applications and challenges","volume":"7","author":"Berger","year":"2015","journal-title":"mAbs"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153509_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.cytox.2021.100058","article-title":"Exclusive inhibition of IL-6 trans-signaling by soluble gp130(FlyR)fc","volume":"3","author":"Berg","year":"2021","journal-title":"Cytokine X"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.153509_bb0175","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00296-009-0885-8","article-title":"IL-6\/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system","volume":"29","author":"Hashizume","year":"2009","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2023.109721","article-title":"Blockade of interleukin-6 trans-signaling prevents mitochondrial dysfunction and cellular senescence in retinal endothelial cells","volume":"237","author":"Hoffman","year":"2023","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155375","article-title":"RNA-Seq analysis reveals gene expression changes induced by IL-6 trans-signaling activation in retinal endothelial cells","volume":"139","author":"Robinson","year":"2021","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153509_bb0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.153509_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB signaling: navigating the network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0200","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1042\/BST20220271","article-title":"ERK1\/2 in immune signalling","volume":"50","author":"Lucas","year":"2022","journal-title":"Biochem. Soc. Trans."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.153509_bb0205","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1172\/JCI57158","article-title":"Therapeutic strategies for the clinical blockade of IL-6\/gp130 signaling","volume":"121","author":"Jones","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.153509_bb0210","doi-asserted-by":"crossref","first-page":"258","DOI":"10.21037\/atm-22-475","article-title":"Circulating exosomal miR-21 mediates HUVEC proliferation and migration through PTEN\/PI3K\/AKT in Crohn's disease","volume":"10","author":"Xie","year":"2022","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.153509_bb0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41419-024-06669-8","article-title":"TMEM9 promotes lung adenocarcinoma progression via activating the MEK\/ERK\/STAT3 pathway to induce VEGF expression","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.153509_bb0220","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23010197","article-title":"beta-Escin effectively modulates HUVECs proliferation and tube formation","volume":"23","author":"Varinska","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0225","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.steroids.2016.09.001","article-title":"Synthetic stigmasterol derivatives inhibit capillary tube formation, herpetic corneal neovascularization and tumor induced angiogenesis: antiangiogenic stigmasterol derivatives","volume":"115","author":"Michelini","year":"2016","journal-title":"Steroids"},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2022.101090","article-title":"Corneal stromal repair and regeneration","volume":"91","author":"Mohan","year":"2022","journal-title":"Prog. Retin. Eye Res."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.153509_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2010.01.039","article-title":"Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis","volume":"117","author":"Bachmann","year":"2010","journal-title":"Ophthalmology"},{"issue":"47","key":"10.1016\/j.ijbiomac.2026.153509_bb0240","doi-asserted-by":"crossref","first-page":"26696","DOI":"10.1039\/C8RA03159B","article-title":"Rhamnazin attenuates inflammation and inhibits alkali burn-induced corneal neovascularization in rats","volume":"8","author":"Yu","year":"2018","journal-title":"RSC Adv."},{"issue":"25","key":"10.1016\/j.ijbiomac.2026.153509_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202400366","article-title":"Platinum nanoparticles regulated V2C MXene nanoplatforms with NIR-II enhanced nanozyme effect for photothermal and chemodynamic anti-infective therapy","volume":"36","author":"He","year":"2024","journal-title":"Adv. Mater."},{"issue":"26","key":"10.1016\/j.ijbiomac.2026.153509_bb0250","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202211432","article-title":"Entropy-mediated high-entropy MXenes nanotherapeutics: NIR-II-enhanced intrinsic oxidase mimic activity to combat methicillin-resistant staphylococcus aureus infection","volume":"35","author":"He","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2025.164582","article-title":"Injectable microcarriers enhance stem cell delivery and promote corneal regeneration for alkali burn","volume":"517","author":"Li","year":"2025","journal-title":"Chem. Eng. J."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.153509_bb0260","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s13346-016-0332-9","article-title":"Rapidly dissolving polymeric microneedles for minimally invasive intraocular drug delivery","volume":"6","author":"Thakur","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.153509_bb0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1167\/tvst.14.11.16","article-title":"Effects of Benzalkonium chloride, a preservative in topical drugs, on the barrier function of human corneal epithelial cells","volume":"14","author":"Zheng","year":"2025","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2020.102342","article-title":"Strategies to prolong the residence time of drug delivery systems on ocular surface","volume":"288","author":"Grassiri","year":"2021","journal-title":"Adv. Colloid Interf. Sci."},{"key":"10.1016\/j.ijbiomac.2026.153509_bb0275","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/IJN.S398769","article-title":"Functional peptide-loaded gelatin nanoparticles as eyedrops for cornea neovascularization treatment","volume":"18","author":"Chu","year":"2023","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153509_bb0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2131\/fts.4.95","article-title":"Repeated-dose ocular instillation toxicity study: a survey of its study design on the basis of common technical documents in Japan","volume":"4","author":"Kurata","year":"2017","journal-title":"Fundam. Toxicol. Sci."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.153509_bb0285","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye (Lond.)"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026034549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:19:59Z","timestamp":1790468399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026034549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":57,"alternative-id":["S0141813026034549"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153509","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant Sgp130 attenuates alkali-burn cornea through inhibition of IL-6 trans-signaling: From production to therapeutic application","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.153509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153509"}}